Key Highlights

  • Novo Nordisk Chief Executive Mike Doustdar defended the company's Diversification strategy a day after its Capital Markets Day failed to reassure investors, with shares falling nearly 8 percent.
  • Doustdar said Novo is actively considering Acquisition opportunities, particularly in areas adjacent to obesity such as cardiovascular disease.
  • The company plans to launch more than five multi-blockbuster drugs by 2030 and target Revenue growth in line with industry peers including Eli Lilly, AstraZeneca and Merck.
  • Doustdar said Novo's oral obesity pills could capture as much as half the global obesity drug market by 2030 as the industry shifts away from weekly injections.

Defending the Strategy a Day After the Selloff

Novo Nordisk (NYSE:NVO) Chief Executive Mike Doustdar defended the company's diversification strategy Tuesday, a day after the drugmaker's Capital Markets Day failed to reassure investors, sending shares down nearly 8 percent in their worst single-day performance since February. Doustdar acknowledged the market reaction directly, saying the company laid out a clearer strategic direction the day before but that investor skepticism signals there is still work to do in building confidence.

Novo outlined plans to launch more than five multi-blockbuster drugs by 2030, targeting more than 150 billion Danish kroner, roughly USD 23 billion, in sales by 2035. The company also guided for revenue growth broadly in line with industry peers including Eli Lilly (NYSE:LLY), AstraZeneca, Amgen, Biogen, Merck, AbbVie and Novartis, a target some investors interpreted as signaling slower growth than previously expected from the company that helped pioneer the modern weight-loss drug market.

Openness to Acquisitions in Adjacent Areas

Doustdar told reporters the company is actively considering Merger and acquisition opportunities as competition in the obesity market intensifies, particularly in areas adjacent to Novo's core Business such as cardiovascular disease. He said Novo recently experienced a setback with its experimental drug ziltivekimab, which failed to reduce the risk of heart attacks in a study earlier this year, and that the company is now assessing whether an external deal could Fill that gap.

He said Novo sees fewer attractive acquisition opportunities within obesity itself, framing the company's dealmaking priorities as concentrated in adjacent disease areas where external innovation could complement its existing pipeline rather than compete directly with it.

A Pill-Led Future and Rebuilding Trust

Separately, Doustdar said Novo's oral obesity pills could capture as much as half the global weight-loss drug market by 2030 as the industry shifts away from weekly injections toward oral treatments, positioning the company's existing oral pipeline and delivery-technology patents as a potential source of competitive advantage. He acknowledged that Novo must do more to rebuild investor trust as the company faces looming Patent expiries for its two flagship drugs, Ozempic and Wegovy, which together account for roughly three-quarters of the company's sales, saying that overpromising and underdelivering has cost the company credibility with investors in recent years.

Outlook

Whether Novo can identify and execute an acquisition in cardiovascular disease or another adjacent area will likely be an early test of Doustdar's diversification strategy, alongside continued scrutiny of the company's oral obesity pipeline progress.